ERBB2 and breast carcinoma: One example is fam-trastuzumab-deruxtecan-nxki, which has been approved in hormone-positive, TNBC (HER2 low, HER2 IHC 1+, 2+) and HER2 breast cancers in metastatic settings based on Destiny trials [235,236].